UCB - Gross Profit On Sales

Stock Price
229.90
Daily Change
-7.10 -3.00%
Monthly
-11.24%
Yearly
43.91%
Q2 Forecast
231.88

UCB reported EUR3.19B in Gross Profit on Sales for its fiscal semester ending in December of 2025.





Gross Profit On Sales Change Date
Alcon AG USD 1.69B 175M Mar/2026
Almirall EUR 429.87M 180.02M Dec/2025
Amarin USD 23.17M 961K Dec/2025
argenx SE USD 1.18B 40.98M Mar/2026
AstraZeneca USD 12.61B 225M Mar/2026
Bayer EUR 6.94B 1.58B Dec/2025
Genmab DKK 977M 13M Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
GRIFOLS EUR 686.84M 56.95M Dec/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.07B 104M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Orion EUR 254M 254.7M Mar/2026
Recordati EUR 472.65M 40.24M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 3.19B 621M Dec/2025
Unibail Rodamco EUR 997M 516.9M Dec/2024